All articles tagged with #eliquis
Bristol Myers Squibb beat expectations on second-quarter adjusted earnings and revenue and lifted its full-year guidance to $49–$50 billion as newer therapies offset declines in legacy drugs; Eliquis grew 21% to $4.48 billion, contributing to the beat and helping lift the stock.
Pfizer beat Q1 2026 estimates with adjusted EPS of 75 cents and revenue of $14.45 billion, reaffirming its 2026 guidance as growth from newly launched and acquired drugs offsets declines in Covid vaccine and Paxlovid sales; the company is pursuing long-term pipeline investments, notably a $10 billion Metsera acquisition, with 2026 targets of about $2.80–$3.00 in adjusted EPS and $59.5–$62.5 billion in revenue.
A NEJM trial comparing apixaban (Eliquis) and rivaroxaban (Xarelto) found Eliquis had a lower risk of clinically relevant bleeding in patients with venous thromboembolism, with similar efficacy in preventing recurrent clots; however, results may not generalize beyond a largely white, healthy population, suggesting Eliquis could be a safer first-line option for many patients.
Bristol Myers Squibb and Pfizer will sell Eliquis directly to patients at over 40% discount, reducing the price from around $606 to $346 per month, as part of efforts to lower drug costs amid government pressure, though the new price remains higher than insurance and Medicare negotiated prices.